Exhibit 99.1 Press Release Novavax Reports First Quarter 2024 Financial Results and Operational Highlights · Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19- Influenza combination vaccines and develop multiple new vaccines utilizing Novavax’s Matrix-M adjuvant · This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including: o $500 million upfront payment o Approximately $70 million equity investment in ...

Novavax (NVAX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $3.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.96%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.49 per share when it actually produced a loss of $1.44, delivering a surprise of -193.88%.Over the last four quarters, the company has surpasse ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 22-2816046 (State or other jurisdictio ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company’s fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal with French pharmaceutical giant Sanofi SA.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Despite reporting a first-quarter loss per share of $1.05, wider than the $0.92 anticipated ...

Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including: $500 million upfront payment Approximately $70 million equity investment in Novavax Up to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royal ...

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company's Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. The licensing agreement will allow Novavax to lift its "going concern" warning ...

  Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients enhanced conve ...

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit ...

High-water price targets from a trio of Wall Street pundits imply three diminutive companies can skyrocket 223% to 557%.Since the page turned to 2023 a little over 16 months ago, the bulls have been running wild on Wall Street. Professional and everyday investors have flocked to high-growth, innovation-driven businesses, and have been particularly enamored with Wall Street's next-big-thing investment trend: artificial intelligence (AI).With AI and machine learning, software and systems are given the ability ...

Novavax (NVAX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move ...